IGF-1 LR3 and BMPs Amplify Ovarian Cell Hormone Output 4–5-Fold in FecB Sheep
Background
The FecB (Booroola) mutation dramatically increases ovulation rate and litter size in sheep by altering the BMPR1B signaling domain — a bone morphogenic protein type-1B receptor. Despite its known effect on follicle development, the precise cellular mechanisms by which the mutation changes the sensitivity of ovarian somatic cells to BMPs and gonadotropins remained poorly characterized. Understanding this pathway matters because BMP signaling governs granulosa cell differentiation, steroidogenesis, and theca cell proliferation — all critical nodes in follicular selection. Standard models lacked a direct side-by-side comparison of FecB-carrier vs. wild-type cell responsiveness under controlled, serum-free conditions, leaving the dose-response landscape undefined.
Study Design
Granulosa cells (GC) and theca cells (TC) were isolated from small (<2 mm) antral follicles of homozygous FecB-carrier (Fec(B/B)) and wild-type (Fec(+/+)) sheep and cultured under serum-free conditions for up to 8 days (96–192 h). Dose-finding experiments used BMP-2, -4, and -6 at 0.005–50 ng/ml, combined with IGF-1 LR3 analog at 0.1–10 ng/ml and gonadotropins (FSH 10 ng/ml; LH for TC). Primary endpoints included ELISA-measured estradiol (E2), inhibin A, and androstenedione production, plus cell proliferation assays. Immunohistochemistry assessed BMP-6 protein localization in antral follicle layers across both genotypes.
Results
All three BMPs equally stimulated E2 production by GCs cultured with FSH, with a clear interaction with IGF-1 LR3 (p < 0.001). BMPs showed no effect on GC proliferation or FSH sensitivity per se. Higher BMP doses (5–50 ng/ml) inhibited LH-stimulated androstenedione production by TCs, while lower doses (0.005–0.05 ng/ml) stimulated TC proliferation (p < 0.01). Critically, hormone production in Fec(B/B) cells consistently outpaced Fec(+/+) cells across matching gonadotropin exposures:
GC output of E2 and inhibin A, and TC output of androstenedione, was 4- to 5-fold greater (p < 0.001) in Fec(B/B) vs. Fec(+/+) cells at equivalent gonadotropin doses.
At low IGF-1 LR3 (0.1 ng/ml), maximum BMP-driven E2 and inhibin A increases in Fec(B/B) GCs occurred at 3–10 ng/ml BMP — a threshold 3- to 10-fold lower than the 30 ng/ml required for wild-type GCs (p < 0.001). Low-dose BMPs stimulated TC proliferation in Fec(+/+) (p < 0.01) but not in Fec(B/B) ewes. Immunohistochemistry confirmed BMP-6 protein expression in oocyte, granulosa, and thecal layers in both genotypes.
Key Findings
- E2, inhibin A, and androstenedione output was 4–5-fold greater (p < 0.001) in Fec(B/B) vs. Fec(+/+) cells at equivalent gonadotropin doses.
- Fec(B/B) GCs reached maximal BMP response at 3–10 ng/ml vs. 30 ng/ml required for wild-type GCs (3–10-fold lower threshold, p < 0.001).
- BMP doses of 5–50 ng/ml inhibited LH-stimulated androstenedione in TCs; lower doses (0.005–0.05 ng/ml) stimulated TC proliferation (p < 0.01).
- Clear IGF-1 LR3 × BMP interaction on GC estradiol production (p < 0.001) confirmed across dose range.
- BMP-6 protein confirmed by immunohistochemistry in oocyte, granulosa, and thecal layers of both Fec(B/B) and Fec(+/+) follicles.
Why It Matters
FecB-carrier ovarian cells require 3–10-fold lower BMP concentrations to mount a maximal steroidogenic response, meaning even trace paracrine BMP signals are sufficient to drive full differentiation — a mechanistic explanation for the mutation's hyperprolificacy. For researchers and clinicians, this implies that BMPR1B gain-of-function phenotypes could be a template for understanding hyperovulatory conditions or designing ovarian stimulation protocols that leverage BMP-IGF-1 crosstalk. The additive interaction between IGF-1 LR3 and BMPs on E2/inhibin A output identifies a dual-pathway leverage point: protocols stacking BMP-pathway agonism with IGF-1 signaling may achieve amplified steroidogenesis at sub-maximal individual doses. Translation to human fertility medicine remains distant; this is an in vitro sheep model, and human BMPR1B variants may not recapitulate identical sensitivity shifts.
